<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E26CBFEF-E84A-4B03-A8AD-D9031C8EAFDF"><gtr:id>E26CBFEF-E84A-4B03-A8AD-D9031C8EAFDF</gtr:id><gtr:name>Medical University of South Carolina</gtr:name><gtr:address><gtr:line1>Medical University of South Carolina</gtr:line1><gtr:line2>171 Ashley Avenue</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/003812CD-18CA-4415-85A0-D112873B652B"><gtr:id>003812CD-18CA-4415-85A0-D112873B652B</gtr:id><gtr:name>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>College of Life Sciences</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E26CBFEF-E84A-4B03-A8AD-D9031C8EAFDF"><gtr:id>E26CBFEF-E84A-4B03-A8AD-D9031C8EAFDF</gtr:id><gtr:name>Medical University of South Carolina</gtr:name><gtr:address><gtr:line1>Medical University of South Carolina</gtr:line1><gtr:line2>171 Ashley Avenue</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/003812CD-18CA-4415-85A0-D112873B652B"><gtr:id>003812CD-18CA-4415-85A0-D112873B652B</gtr:id><gtr:name>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D25E5CC6-E888-4C36-B940-B2FC4C764251"><gtr:id>D25E5CC6-E888-4C36-B940-B2FC4C764251</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Downes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9403619"><gtr:id>FCEAB9F9-3FE2-43FF-90BC-51A02E883D94</gtr:id><gtr:title>Spatial, temporal and metabolic regulation of PI 3-kinase derived lipid signals in health and disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9403619</gtr:grantReference><gtr:abstractText>The correct functions of our cells and tissues are controlled by a wide range of signalling molecules such as hormones and growth factors. These usually bind to receptors on the outer surface of cells and trigger the production of intracellular signals called second messengers. We study a special class of second messengers called inositol phospholipids and one in particular which is phosphatidylinositol trisphosphate or PIP3. PIP3 is the second messenger produced by insulin action and it plays an important role in controlling the amount of sugar in the blood. Failure to produce PIP3 in insulin responsive tissues after a meal is a major cause of diabetes. Cells control PIP3 levels through enzymes that make it, called PI 3-kinases, and other enzymes, called phosphatases, which destroy it. Mutations in one of the PI 3-kinases which cause its activation at the wrong time can cause cancer and occur commonly in breast and colon tumours whilst inactivating mutations in one of the phosphatases, called PTEN, cause many other tumours. We study the regulation of PI 3-kinase signalling especially focussing on the phosphatases that destroy PIP3. We collaborate with several large pharmaceutical companies who are targeting PI 3-kinase signalling to develop drugs for the treatment of cancer, type 2 diabetes and inflammatory diseases.</gtr:abstractText><gtr:technicalSummary>Inositol glycerophospholipids are amongst the most versatile intracellular signal molecules whose functions include acting as second messengers in response to hormones and growth factors and the regulation of membrane trafficking events. There are currently eight known species which differ with respect to the number and distribution of phosphate groups around the inositol ring and they function by binding to effector proteins which possess lipid binding domains many of which are highly specific for a particular headgroup configuration. This programme focuses on phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), the product of type I phosphoinositide 3-kinases (PI 3-kinases) and PtdIns(3,4P)P2, produced mainly by the action of 5-phosphatases on the former lipid signal. PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a tumour suppressor that inactivates PtdIns(3,4,5)P3 by hydrolysing the 3-phosphate. Fundamental studies of PTEN mechanism and membrane targeting will be continued. We discovered that PI 3-kinase signalling can be stimulated by reactive oxygen species (ROS) which inactivate PTEN through reversible oxidation of the active site cysteine and we have preliminary evidence that PtdIns(3,4)P2 is also metabolised by a redox-sensitive phosphatase. The roles of endogenously generated ROS in regulating these enzymes and hence PI 3-kinase lipid products will therefore be studied in cell lines and extended to xenograft models of solid tumours. We have also exploited a range of lipid binding protein domains to develop a suite of methods that allow quantitative and spatial analysis of lipid signals in enzyme assays, live cells and subcellular structures, the latter using immuno-electron microscopy. These approaches will be used to study localised generation and metabolism of signalling lipids in polarised cellular responses such as the formation of macropinosomes in dendritic cells and on the dendritic cell side of the ?immune synapse? between these cells and T-cells, as well as in models of disease. The ultrastuctural studies aim to determine the molecular basis for the occurrence of PI 3-kinase lipid products in many cellular compartments including identifiying the isoforms of enzymes involved in their synthesis and metabolism and the identification of novel PtdIns(3,4,5)P3 binding proteins. Further work will lead to the development of improved methods for measuring protein/lipid interactions and for the detection of PtdIns(3,4,5)P3 in small cell numbers sorted by FACS analysis. Lastly we will study novel mechanisms of feedback regulation of insulin simulated PI 3-kinase responses that may contribute to an insulin resistant state.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1994-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4214154</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Commercial service collaboration - Novartis</gtr:description><gtr:id>A69F735F-FE41-4BC3-94F5-A6A97901ECD7</gtr:id><gtr:impact>We obtained scientifically valuable data from several control compounds and supplied data to Novartis regarding their test compounds.</gtr:impact><gtr:outcomeId>czjKPAYjNwc-1</gtr:outcomeId><gtr:partnerContribution>It motivated us to test several control compounds as inhibitors of the tumour suppressor phosphatase PTEN</gtr:partnerContribution><gtr:piContribution>We tested several compounds for their ability to inhibit PTEN in vitro</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:department>Institute for Molecular Medicine</gtr:department><gtr:description>Academic collaboration - Joao Barata</gtr:description><gtr:id>A83BF6B6-D446-42E3-8F8B-F4189CF22BD8</gtr:id><gtr:impact>Publication. PM ID: 18830414</gtr:impact><gtr:outcomeId>384DACB5B2B-1</gtr:outcomeId><gtr:partnerContribution>Sharing reagents and unpublished data</gtr:partnerContribution><gtr:piContribution>Sharing data and reagents and hosting a visiting student to analyse samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of South Carolina</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Academic collaboration - Carola Neumann</gtr:description><gtr:id>67F00645-FCDC-4A8A-8FD3-7AE0FA910B3D</gtr:id><gtr:impact>Publications: PM ID 19369943 and unpublished data</gtr:impact><gtr:outcomeId>1564E6016C1-1</gtr:outcomeId><gtr:partnerContribution>Provided reagents and shared data to pursue collaborative work</gtr:partnerContribution><gtr:piContribution>Sharing reagents and data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Developmental Neurobiology</gtr:department><gtr:description>Academic collaboration - Britta Eickholt</gtr:description><gtr:id>04E35E25-C965-40E1-BF2A-2219111D4FF0</gtr:id><gtr:impact>3 research Publications: 
PubMed IDs: 19767745, 23940795, 23085752</gtr:impact><gtr:outcomeId>73F3152501A-1</gtr:outcomeId><gtr:partnerContribution>The Eickholt lab have provided reagents and shared unpublished data to allow collaborative projects. They also hosted an NRL lab postdoctoral researcher working in the Eickholt lab in Berlin for 2 months in 2013</gtr:partnerContribution><gtr:piContribution>Extensive academic collaboration, involving reagent exchange, sharing ideas and data. One postdoctoral researcher worked in the Eickholt lab in Berlin for 2 months in 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dundee Signal Transduction Therapy (DSTT) Consortium</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DSTT Pharameutical Consortium</gtr:description><gtr:id>6C934958-DF2D-41B8-A889-AB454A5F1408</gtr:id><gtr:impact>The collaboration has supported the drug discovery efforts of 6 major global pharmaceutical companies in the field of PI 3-Kinase signalling, an extrememly active area, especially for cancer. The collaboration has supported 2 or 3 research posts in the core CPD/NRL labs since its inception in 1998 contributing to many of the CPD lab publications over this time. It has also funded a level of around ten active laboratory positions since 1998, with these trained staff going into further academic and commercial positions.</gtr:impact><gtr:outcomeId>9C6102F3F89-1</gtr:outcomeId><gtr:partnerContribution>We have had occasional access to novel compounds from these pharmaceutical collaborators for use as experimental enzyme inhibitors in our research. Extensive interactions with the pharmaceutical collaborators has also been effectiove in broadening the translational training of the research team.</gtr:partnerContribution><gtr:piContribution>The collaboration is funded by a pharmaceutical consortium, supporting several activities including a research Division sited in the University of Dundee College of Life Sciences. From 1998-2012 this was overseen by the co-directors, Peter Downes, the original PI on this grant and Professors Philip Cohen and Dario Alessi. Dr Leslie and Prof Downes and their research groups also provided advice and expertise to the consortium companies. Since the last renewal of the collaboration in 2012, the grant holders have not been formally involved but occasionally act as informal consultants to the consortium companies, the last instance being in October 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Cell and Developmental Biology</gtr:department><gtr:description>Academic collaboration - Kees Weijer</gtr:description><gtr:id>B56DFC20-F23E-490A-9C9D-F2DE4AE35CF5</gtr:id><gtr:impact>Publications: PM IDs: 17240336, 19915616, 16246156 and unpublished data</gtr:impact><gtr:outcomeId>C069EB39648-1</gtr:outcomeId><gtr:partnerContribution>Sharing data and providing novel experimental capabilities within a shared project</gtr:partnerContribution><gtr:piContribution>Sharing data and reagents within a shared project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medicine, Dentistry &amp; Nursing</gtr:department><gtr:description>Academic collaboration - Seth Schorr</gtr:description><gtr:id>32576A4B-DCCC-4FC0-B8E8-AFBF9E20D96A</gtr:id><gtr:impact>Publication: Ellis et al, PMID: 20600851</gtr:impact><gtr:outcomeId>pSrsEEbLr3x-1</gtr:outcomeId><gtr:partnerContribution>Extensive experimnetal collaboration, significant scientific dialog, and experiments mostly performed by rsesearchers funded from collaborators lab.</gtr:partnerContribution><gtr:piContribution>Project instigation and direction. Some experiments. Writing and over-seeing publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Academic collaboration - Britta Eickholt</gtr:description><gtr:id>B84E5D1E-E02B-428C-854C-9F1584ED674D</gtr:id><gtr:impact>3 research Publications: 
PubMed IDs: 19767745, 23940795, 23085752</gtr:impact><gtr:outcomeId>73F3152501A-2</gtr:outcomeId><gtr:partnerContribution>The Eickholt lab have provided reagents and shared unpublished data to allow collaborative projects. They also hosted an NRL lab postdoctoral researcher working in the Eickholt lab in Berlin for 2 months in 2013</gtr:partnerContribution><gtr:piContribution>Extensive academic collaboration, involving reagent exchange, sharing ideas and data. One postdoctoral researcher worked in the Eickholt lab in Berlin for 2 months in 2013.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Biomolecular Sciences</gtr:department><gtr:description>Acadamic collaboration - Rick Randall</gtr:description><gtr:id>ACAA6616-79D0-4AD5-B849-80B432C098D9</gtr:id><gtr:impact>Publications: PM ID: 18029356 and 20133840</gtr:impact><gtr:outcomeId>D1CB484089C-1</gtr:outcomeId><gtr:partnerContribution>Sharing unpublished data</gtr:partnerContribution><gtr:piContribution>Sharing data and analysing samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press and media coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>37073C9E-BB2D-4FD9-8FA9-84FF41D8C533</gtr:id><gtr:impact>Peter Downes and Nick Leslie have been interviewed by press and television to discuss individual research publications.

MRC funded work in the CPD/NRL laboratory is also of great interest to the pharmaceutical industry and underpined the ground breaking collaboration between Dundee scientists and five leading pharmaceutical companies known as the Division of Signal Transduction Therapy (DSTT). Peter Downes was a founding co-director of DSTT which has attracted much external interest 1998-2012. During the period of support we have hosted at least eight visits from members of the international press and other publishing activities, Scottish and international development agencies and industry.

Elevated profile of MRC funded research and its translation to drug discovery through collaboration with global pharmaceutical companies. The PI3K pathway which is the subject of this funding and which was co-discovered by Peter Downes, is one of the most fertile areas of mechanism based drug dicovery, especially relating to human cancer.</gtr:impact><gtr:outcomeId>387F90C7FC0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>College Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FC8CF25B-1A44-405E-B865-C5344FA65D26</gtr:id><gtr:impact>Several group members presenting science at College Open Day

High attendence (around 300)</gtr:impact><gtr:outcomeId>gWSmZGRMce1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit from School pupils - Madras Academy St Andrews</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>6B504777-0BAB-4920-86BD-AEA67162EF2B</gtr:id><gtr:impact>A seminar regarding our research and careers in science

Good positive feedback</gtr:impact><gtr:outcomeId>FE9C37FC2F7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School and early undergraduate project placements</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44CF31AA-9F35-41F5-A6EA-556FCBF85332</gtr:id><gtr:impact>We regularly host laboratory placements for school and early undergraduate students to experience research

To my knowledge, all of these students have entered University scientific degree programmes or in the case of relevant undregraduates continued a research/scientific career</gtr:impact><gtr:outcomeId>D21D244924A</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC CASE Studentship (Bohringer Ingelheim)</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>24250A15-1005-4B6A-A44A-7C33ED76D735</gtr:id><gtr:outcomeId>B96812880340</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250746</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DTI: Succeeding Through Innovation</gtr:description><gtr:fundingOrg>Department for Business, Energy &amp; Industrial Strategy</gtr:fundingOrg><gtr:id>7FB6CD22-D88A-48C9-8D1C-E09CA43B80ED</gtr:id><gtr:outcomeId>CD3C590F4070</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The development of a lipid kinase selectivity screen is not strictly a discovery, but it requires a high level of expertise and reputation in the lipid signalling field as well as the resources required to generate large quantities of many enzymes grouped together under a single assay platform. We also have 'first mover' advantage in terms of the marketability of the screen and existing collaborators in the form of the DSTT member pharmaceutical companies.</gtr:description><gtr:grantRef>G9403619</gtr:grantRef><gtr:id>C0C91D5A-BBFC-4E97-893F-B4B96A5612C5</gtr:id><gtr:impact>A screen which supports and drives PI 3-kinase pathway drug discovery within 5 major pharmaceutical companies.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>D57A83B4AD7</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Lipid kinase selectivity screen</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An extensive range of expression constructs (plasmids and viral vectors) for use in several systems.</gtr:description><gtr:id>002291C3-B874-4D3B-B66E-E9FFB7CF9F8C</gtr:id><gtr:impact>We frequently supply other academic research groups with expression constructs (approx 10-15 times per year). Some of these interactions take the forms of collaborations, others simply acknowledged reagent supply. These reagents have been used in many subsequent published projects.</gtr:impact><gtr:outcomeId>70898E27E8A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Expression construct collection</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Purified polyclonal antibodies produced during research programme</gtr:description><gtr:id>4EC59A9B-B391-468F-A572-083C52046162</gtr:id><gtr:impact>Research publications and progress</gtr:impact><gtr:outcomeId>097191A06C8</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This is a service provided to our pharmaceutical collaborators and the broader academic community supporting drug discovery efforts in the area of PI3K. It is the first of its kind developed within an academic setting.</gtr:description><gtr:id>C3B92AD7-9EB2-4DE5-A036-4A0112338BE2</gtr:id><gtr:impact>Supports intensive research in 5 global pharmaceutical companies developing novel cancer treatments targeting the PI 3-kinase pathway. Will develop a large data matrix relating compound structures to efficacy against a large number of lipid kinase enzymes.</gtr:impact><gtr:outcomeId>3F5523B4C97</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Lipid Kinase selectivity screen</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.kinase-screen.mrc.ac.uk/kinase-lipid-kinase-panel</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>777D6423-9A17-4542-91DA-709382A4AB11</gtr:id><gtr:title>Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3680b3b9762e33c97e20feae25aa79a5"><gtr:id>3680b3b9762e33c97e20feae25aa79a5</gtr:id><gtr:otherNames>Maccario H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>tm4PK4Qw7uv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E245D33-8D8E-4BA2-8141-21BD658710D5</gtr:id><gtr:title>A screen for novel phosphoinositide 3-kinase effector proteins.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10c5072ac3714a910a28244aeee2b690"><gtr:id>10c5072ac3714a910a28244aeee2b690</gtr:id><gtr:otherNames>Dixon MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>RYWRs8dfcL5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7F97C9A-61BF-4763-A4BD-E630D5C4C461</gtr:id><gtr:title>Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/006ba0dc1da4463f740972bda069132f"><gtr:id>006ba0dc1da4463f740972bda069132f</gtr:id><gtr:otherNames>Davidson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>HXHEeGZAZZe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38441ACC-5253-40A9-AFEC-0571589416F8</gtr:id><gtr:title>Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6f11ff9dfccb463af84716db11ca95e"><gtr:id>a6f11ff9dfccb463af84716db11ca95e</gtr:id><gtr:otherNames>Steelman LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>HHQkqGnKMKJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C47CD34C-0F10-4739-9AB1-6276BB4F32B5</gtr:id><gtr:title>Mechanism of activation of PKB/Akt by the protein phosphatase inhibitor Calyculin A.</gtr:title><gtr:parentPublicationTitle>Cell biochemistry and biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/585617eaa3947795ff0812199452f105"><gtr:id>585617eaa3947795ff0812199452f105</gtr:id><gtr:otherNames>Pozuelo-Rubio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1085-9195</gtr:issn><gtr:outcomeId>SmYuhzvk9MQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B19C01F-D89A-4A4C-9A45-7D5C217097A8</gtr:id><gtr:title>Regulation of insulin receptor substrate 1 pleckstrin homology domain by protein kinase C: role of serine 24 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Molecular endocrinology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bace3d3a2f29465fff6466bfac7c566"><gtr:id>8bace3d3a2f29465fff6466bfac7c566</gtr:id><gtr:otherNames>Nawaratne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0888-8809</gtr:issn><gtr:outcomeId>67B99102C65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48A3CC07-B168-4F43-B852-791F23A68010</gtr:id><gtr:title>MyosinV controls PTEN function and neuronal cell size.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b569d3769fdd6f083933ef62744f7a5"><gtr:id>7b569d3769fdd6f083933ef62744f7a5</gtr:id><gtr:otherNames>van Diepen MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>FCD44986C3D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1646A7A-FDDC-4EDF-B1B5-89C7A45F610A</gtr:id><gtr:title>IQGAP proteins reveal an atypical phosphoinositide (aPI) binding domain with a pseudo C2 domain fold.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10c5072ac3714a910a28244aeee2b690"><gtr:id>10c5072ac3714a910a28244aeee2b690</gtr:id><gtr:otherNames>Dixon MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_15109_29_22493426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B76EBDF-D282-48D0-97A3-62A05CAA6B1B</gtr:id><gtr:title>PTEN is destabilized by phosphorylation on Thr366.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3680b3b9762e33c97e20feae25aa79a5"><gtr:id>3680b3b9762e33c97e20feae25aa79a5</gtr:id><gtr:otherNames>Maccario H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>911F5FFFA71</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DF87D0E-3144-4AC0-A8D8-1CDA7F589277</gtr:id><gtr:title>Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fa4e8e0c4dd125db4bee84dfdc71abd"><gtr:id>6fa4e8e0c4dd125db4bee84dfdc71abd</gtr:id><gtr:otherNames>Hale BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>1422BD7E45F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9360B77-7603-4A0C-84AF-C744CE368BDC</gtr:id><gtr:title>PTEN inhibitors: an evaluation of current compounds.</gtr:title><gtr:parentPublicationTitle>Advances in biological regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2212-4926</gtr:issn><gtr:outcomeId>56dda5ea56e1a8.38099161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35877F2C-8019-4E38-8C5D-92543CEC2D36</gtr:id><gtr:title>Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN</gtr:title><gtr:parentPublicationTitle>CELL BIOLOGY OF INOSITOL LIPIDS AND PHOSPHATES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b81d0151b7ff16ae5c6c0253498dd36f"><gtr:id>b81d0151b7ff16ae5c6c0253498dd36f</gtr:id><gtr:otherNames>Downes C. Peter</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:isbn>978-1-85578-166-5</gtr:isbn><gtr:issn>0067-8694</gtr:issn><gtr:outcomeId>5a35190ee20317.12480693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FDD50EC-38F8-40DB-9A1F-3BC3F444E8C3</gtr:id><gtr:title>Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9946144ae62da37ee90f7ccd99565e9f"><gtr:id>9946144ae62da37ee90f7ccd99565e9f</gtr:id><gtr:otherNames>McEwan DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>NVNfnJySBxV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4886C037-8C7F-468D-9F70-3F92F6D11333</gtr:id><gtr:title>Non-genomic loss of PTEN function in cancer: not in my genes.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>BvBjStAcj2N</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AC4AACC-2E00-4871-80ED-7FE92BF14A1F</gtr:id><gtr:title>Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN.</gtr:title><gtr:parentPublicationTitle>Biochemical Society symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3641eb96160646e7123bbfdf914c3934"><gtr:id>3641eb96160646e7123bbfdf914c3934</gtr:id><gtr:otherNames>Downes CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0067-8694</gtr:issn><gtr:outcomeId>191F3BBBFE5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CE536F1-8980-45AC-8B49-00E6A9D343E9</gtr:id><gtr:title>A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86bf9df4c88035dcd21eadacdccab2ef"><gtr:id>86bf9df4c88035dcd21eadacdccab2ef</gtr:id><gtr:otherNames>Ning K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>84274CF577E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E816DC26-B6EA-4971-8C53-728243E2F80D</gtr:id><gtr:title>A fluorescence lifetime-based assay for serine and threonine kinases that is suitable for high-throughput screening.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7ef8c36f8ae319b09dc632c5c38e824"><gtr:id>b7ef8c36f8ae319b09dc632c5c38e824</gtr:id><gtr:otherNames>Paterson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>dDfVtn6RB42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C20ED5D2-FD77-4909-BEF5-AB5043146483</gtr:id><gtr:title>Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4eaac07ba1d7fbd16739546e91b81702"><gtr:id>4eaac07ba1d7fbd16739546e91b81702</gtr:id><gtr:otherNames>Green CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>RmhjH6YE4Cz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E3CF803-B346-4515-904E-9BA7F12009F6</gtr:id><gtr:title>Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110a/PIK3CA but not by HER2 or mutant AKT1.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb6178f3d8f8a863ab7fdd12cb72e4b1"><gtr:id>eb6178f3d8f8a863ab7fdd12cb72e4b1</gtr:id><gtr:otherNames>Berglund FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_15109_29_23085752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0070734-0C3E-4C91-AF5B-31ACA471685C</gtr:id><gtr:title>Assaying PTEN catalysis in vitro.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>56dda5ea2e9f60.00052270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF260AAE-0DBE-4617-A5CF-1D53F526A4B4</gtr:id><gtr:title>Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9712998a8e9e09ad720a8a51a65ba01a"><gtr:id>9712998a8e9e09ad720a8a51a65ba01a</gtr:id><gtr:otherNames>Ellis IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>Bkp8zpRtosC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFE33DD4-B64A-44E4-93F6-20DF3C9D2F27</gtr:id><gtr:title>Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab38f98efdaaa2792856340a1d9bffe"><gtr:id>4ab38f98efdaaa2792856340a1d9bffe</gtr:id><gtr:otherNames>Lindsay Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>049644D8D69</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FFB6D0C-CD79-446F-8634-8ACDAE241B94</gtr:id><gtr:title>Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96f1e2aaea980517d79c80f654eb2004"><gtr:id>96f1e2aaea980517d79c80f654eb2004</gtr:id><gtr:otherNames>Garc?a-Mart?nez JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>nfyeweQwFGD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EA55E6D-EDD5-442F-8D67-74322DF36FBD</gtr:id><gtr:title>Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67890bdd6eca08bd11a9ac31e2a1ece6"><gtr:id>67890bdd6eca08bd11a9ac31e2a1ece6</gtr:id><gtr:otherNames>Sinclair LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>U87xWwnZpN5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EFBB169-1EE0-4F0D-BC04-28AFFFA4DD0F</gtr:id><gtr:title>Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c7895cd92b2c830a929706fb4aad8e"><gtr:id>11c7895cd92b2c830a929706fb4aad8e</gtr:id><gtr:otherNames>Lackey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>0673557F5F0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1F36E49-CEDA-4420-8050-ACBBC6B97B27</gtr:id><gtr:title>Activity of any class IA PI3K isoform can sustain cell proliferation and survival.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/feaeb1b73f83de9d7c3eae4d3152e7ac"><gtr:id>feaeb1b73f83de9d7c3eae4d3152e7ac</gtr:id><gtr:otherNames>Foukas LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BhJnpGkefZf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D33BB01-EFB5-4A22-9871-CBA8D4C5D69C</gtr:id><gtr:title>Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9388530a23d77d80cd9d8c73f76a35"><gtr:id>2d9388530a23d77d80cd9d8c73f76a35</gtr:id><gtr:otherNames>Cao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>BAf1QbwKB1Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC5BE169-B19B-4C73-8A72-A16C9999E5E9</gtr:id><gtr:title>Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases.</gtr:title><gtr:parentPublicationTitle>Advances in biological regulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2212-4926</gtr:issn><gtr:outcomeId>XTmC8bHtThR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A29DA1B1-7D84-4D93-A7F3-2A3F28A98DA2</gtr:id><gtr:title>Leptin regulates AMPA receptor trafficking via PTEN inhibition.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b776dfe698d77f95889b417812608a15"><gtr:id>b776dfe698d77f95889b417812608a15</gtr:id><gtr:otherNames>Moult PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>Pbgz4dKTUsF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E145011C-AF76-42EF-87B9-8C552D42A4FD</gtr:id><gtr:title>Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71199c576f86dc8873643b3f7f6cd728"><gtr:id>71199c576f86dc8873643b3f7f6cd728</gtr:id><gtr:otherNames>Wullschleger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>hnm3QchKvrz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ED001C2-BA6B-4789-A975-478BCA5C8AAC</gtr:id><gtr:title>Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0523f73515aa96c419fadff649cba6a"><gtr:id>d0523f73515aa96c419fadff649cba6a</gtr:id><gtr:otherNames>Spinelli L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>56dda5ea7b4c60.45552962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BF3C1D6-E1A4-432E-8FC8-83A12067D075</gtr:id><gtr:title>Characterization of a selective inhibitor of inositol hexakisphosphate kinases: use in defining biological roles and metabolic relationships of inositol pyrophosphates.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/715d04fe6268cf01f208b496254b94e1"><gtr:id>715d04fe6268cf01f208b496254b94e1</gtr:id><gtr:otherNames>Padmanabhan U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CC8F4C1FE37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D118A842-C629-460E-A149-1EFA2D08DE8D</gtr:id><gtr:title>The control of phosphatidylinositol 3,4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5af10630327544a0302a2a6e1d892d6d"><gtr:id>5af10630327544a0302a2a6e1d892d6d</gtr:id><gtr:otherNames>Batty IH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>75B91E0CFB2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21AE23F9-88B4-42AC-845D-FE2646A7DE86</gtr:id><gtr:title>Understanding PTEN regulation: PIP2, polarity and protein stability.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>ED915D504AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF13B1F2-1685-4BD4-9D7A-7E7E073205BF</gtr:id><gtr:title>Controlling PTEN (Phosphatase and Tensin Homolog) Stability: A DOMINANT ROLE FOR LYSINE 66.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58c2b946a3d1e5.31780410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C17DB3-85D3-462C-83F8-C6A3B8EF454F</gtr:id><gtr:title>PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e78620a0072abfc94b6484167862045"><gtr:id>8e78620a0072abfc94b6484167862045</gtr:id><gtr:otherNames>Silva A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>hnJiabmZ8sE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D00763D-2DD0-4374-827A-7E842D19BE2A</gtr:id><gtr:title>PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4261451fb9912c6a602ad8d818b81701"><gtr:id>4261451fb9912c6a602ad8d818b81701</gtr:id><gtr:otherNames>Tibarewal P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>pm_15109_29_22375056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A55535AB-3C89-4D34-816B-2DA58A60EA42</gtr:id><gtr:title>Differential redox regulation within the PTP superfamily.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b556b90a2ca1b7e3e17ad24d77f1e5d"><gtr:id>9b556b90a2ca1b7e3e17ad24d77f1e5d</gtr:id><gtr:otherNames>Ross SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>719A04699B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6701210-B8FD-442C-88E8-61DA806C838B</gtr:id><gtr:title>Use of the GRP1 PH domain as a tool to measure the relative levels of PtdIns(3,4,5)P3 through a protein-lipid overlay approach.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7bc540fe332f484f618d6975a8c480"><gtr:id>ac7bc540fe332f484f618d6975a8c480</gtr:id><gtr:otherNames>Guillou H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>GTCiUkY2vrX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA92EAD3-F7DA-4767-8B3C-8ECB47195B86</gtr:id><gtr:title>PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3dd667e34895468172d0d67b7c31b27"><gtr:id>e3dd667e34895468172d0d67b7c31b27</gtr:id><gtr:otherNames>Leslie NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>ACDDB1D9898</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9403619</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>